VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL)

Inclusion Criteria: * willingness to take the study drug and ability to take oral medications * able to be contacted by phone * willing and able to give informed consent for participation in the study and agrees with its conduct and willing to email the study team a picture of their consent form Exclusion Criteria: Exclusion Criteria Based on National VA Data: We will exclude individuals based on the following national VA data and chart review criteria: * eGFR \<30mL/min or dialysis * aspartate transaminase (AST) or alanine transaminase (ALT) \>5 times the upper limit of normal or cirrhosis in past 2 years * hypersensitivity to chloroquine, hydroxychloroquine or other 4-aminoquinolines (e.g., amodiaquine), azithromycin or macrolides * already taking hydroxychloroquine or azithromycin * congestive heart failure with an ejection fraction (EF) \<35% in past 2 years or hospitalization within past 6 months * concomitant treatment with any QT prolonging drug * history of cardiac arrest, ventricular fibrillation or ventricular tachycardia in past 5 years * QT prolongation on any ECG in past 5 years * potassium \<3.5 meq/l in labs in past 2 years * magnesium\< 1/5 meq/l in any lab in past 2 years * any patient who has not had follow-up with their primary care doctors in past 2 years * any Veteran who cannot follow-up such as those with dementia, home based primary care or those with active psychosis documented in past 2 years * G6PD deficiency Exclusions Based on Baseline Interview: * any female who is breastfeeding or pregnant or planning to become pregnant. * any Veteran who receives most of their care in non-VA settings * Veteran enrolled in another COVID Trial * Veteran received a prescription for azithromycin and hydroxychloroquine * Veteran allergic to azithromycin and or hydroxychloroquine * Veteran receiving QT prolonging drugs from non-VA pharmacy